Compare Incyte Corporation (INCY) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs JetBlue Airways Corporation — how do they compare? Incyte Corporation trades at $112.68 (market cap $22.85B), while JetBlue Airways Corporation trades at $3.87 (market cap $1.48B). The key difference: Incyte Corporation is far larger — about 15.4× JetBlue Airways Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and JetBlue Airways Corporation for 44 Days on average.
| INCY | JBLU | |
|---|---|---|
Market Cap | $22.85B | $1.48B |
Volume | 1,927,029 | 30,275,693 |
Sector | Health | Industrials |
52-Week High | $129.93 | $6.46 |
52-Week Low | $83.80 | $3.92 |
Typical Hold Time | 33 Days | 44 Days |
Enterprise Value | $18.35B | $8.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
JetBlue (JBLU) trades at $3.97, down 1.49% today, with a bearish technical outlook despite oversold RSI levels. The airline faces fundamental challenges with consecutive quarterly losses, negative profit margins (-9.32%), and elevated debt levels (debt-to-asset ratio of 51.28% in 2025). Recent developments include route expansion to Colombia and the launch of premium BlueFirst seating, but operational cash flow remains negative (-$94M in 2025).
The investment outlook is cautious given persistent losses and high leverage, though the current valuation (P/S 0.15, P/B 0.93) appears discounted. Analyst consensus is mixed with a $5.89 price target (48% upside) but predominantly Hold ratings (62%). Key risks include fuel cost volatility, competitive pressure, and macroeconomic sensitivity to travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
